PROCEPT BioRobotics Corporation (PRCT)
NEUTRALFundamental
39
Kurs
$21.50
Marktkapitalisierung
$1.20B
Teil 1 · Was das Unternehmen wert ist
Übersicht
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
$337M
Letzte 12 Monate (bis 30.6.2026)
Nettogewinn
$-110M
Letzte 12 Monate (bis 30.6.2026)
Freier Cashflow
$-58M
Gesamtes Eigenkapital
$366M
Gesamtverbindlichkeiten
$142M
Current Ratio
6.55
Zinsdeckungsgrad
32.88
Schulden/EBITDA
-
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$21.64
Aktueller Kurs
$21.50
Sicherheitsmarge
+0.6%
Innerer-Wert-Spanne
$20.55 - $22.72
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
-
ROE
-26.1%
P/B-Verhältnis
3.58
P/FCF
-
Bruttomarge
64.2%
ROIC
-21.7%
Rentabilitäts-Radar
Value Creation (Economic Moat)
ROIC
-21.7%
WACC
9.3%
ROIC − WACC
-31.0 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamentalanalyse-Kriterien
Bestanden (8)
- EPS shows upward trend
- Gross Margin 64.2%
- Debt/Equity ratio
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Revenue Growth 5Y 109.0%
- Analyst Consensus 57% Buy
Nicht bestanden (12)
- Price CAGR -2.82%
- ROIC -21.7%
- P/B Ratio 3.58
- Operating Margin -33.9%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -30.6%
- Earnings Surprise avg -12.6%
- Share Dilution 6.4%
- Net Margin Trend -32.5% vs -30.6%
- Piotroski F-Score 3/9
Nicht verfügbar (7)
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Ernsthafte finanzielle Bedenken
Gewinnqualität
Niedrige Qualität: Rechnungslegung prüfen
Aktienverwässerung
Neue Aktien werden ausgegeben, Eigentum wird verwässert
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Mr. Larry L. Wood | President, CEO & Director | 59 |
| Mr. Kevin Waters | Executive VP & CFO | 48 |
| Ms. Alaleh Nouri | EVP, Chief Legal Officer & Corporate Secretary | 46 |
| Mr. Christofer Christoforou | Executive Vice President of Operations | 55 |
| Mr. Barry Templin | Executive VP & CTO | - |
| Mr. Matthew James Bacso C.F.A. | Vice President of Investor Relations | - |
| Ms. Pooja Sharma Rao | Executive VP and Chief Strategy & Marketing Officer | - |
| Ms. Stacey L. Porter | Executive VP & Chief People Officer | 50 |
| Mr. Bijesh Chandran | Executive Vice President of Regulatory Affairs & Quality Assurance | - |
| Mr. Stephen J. McGill | Senior VP & GM of International | 63 |
Prüfungsrisiko
6
Vorstandsrisiko
5
Vergütungsrisiko
10
Aktionärsrechterisiko
8
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for PRCT, sourced from Markets Gazette.